SIZE XSSIZE SMSIZE MDSIZE LG

Updates from American Society of Clinical Oncologist (ASCO) – Hematology Focus

September 27, 2018
5:00 – 6:00 pm Central

Credits: 1 hour BCOP and/or 1 hour ACPE
BCOP credits are available to earn until March 26, 2019

Individual webinar pricing: $40 (member) / $70 (non-member)

Register Now

This may also be purchased as part of the 2018 BCOP Webinar Bundle.

HOPA is pleased to present the fourth of a five-webinar series, which will review key findings from clinical and translational research, and data presented at national oncology meetings.

This session will highlight significant research developments and treatment advances from the ASCO annual meeting. Selected topics will feature innovations in therapies for hematologic malignancies and supportive care interventions for adults and children with cancer.

Learning Objectives

  • Interpret research findings of key abstracts in hematological malignancies presented at the American Society of Clinical Oncology (ASCO) 54th Annual Meeting.
  • Discuss incorporating emerging therapies and novel treatment strategies into clinical practice.
  • Review chimeric antigen receptor therapies (CAR) T-cell therapy data in hematological malignancies presented at the ASCO Annual Meeting.

Speaker

education speaker david deremer

Dr. David DeRemer, PharmD FCCP BCOP

Dr. David DeRemer, PharmD FCCP BCOP, is a Clinical Associate Professor at the University of Florida College of Pharmacy. He serves as the Assistant Director of the Experimental Therapeutics Incubator at the UF Health Cancer Center (UFHCC) and is active collaborator in early phase UFHCC clinical trials. He received his B.S. Biology and Pharm.D. degrees from the University of Kentucky. Following graduation, he completed a Pharmacy Practice Residency and Oncology residencies at the University of Kentucky Chandler Medical Center. He also completed an Oncology Postdoctoral Fellowship focusing on Drug Discovery/Development at the University of Kentucky.

Disclosure: No financial relationships exist with commercial interests.

Target Audience

This activity is intended for intermediate/advanced hematology/oncology pharmacists. This activity has been approved for 1 contact hour (.1 CEUs) under the ACPE universal activity number 0465-0000-18-054-H04-P.

Activity Type:

Application

Accreditation Statement:

logo acpeThe Hematology/Oncology Pharmacy Association (HOPA) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. An ACPE statement of credit will be issued only upon completion of the pre/post- assessment and a post-activity evaluation form. The Hematology/Oncology Pharmacy Association (HOPA) is accredited by the Board of Pharmacy Specialties (BPS) as a provider of board certification oncology credit (BCOP). A BCOP statement of credit will be issued only upon completion of a post-activity evaluation form and posttest, with a passing grade of 75% achieved. BCOP test must be completed by March 26, 2019.

education speaker bpslogoThe Hematology/Oncology Pharmacy Association (HOPA) is accredited by the Board of Pharmacy Specialties (BPS) as a provider of board certification oncology credit (BCOP). A BCOP statement of credit will be issued only upon completion of a post-activity evaluation form and posttest, with a passing grade of 75% achieved. Test must be completed by March 26, 2019.

Disclosure of Conflicts of Interest: The Hematology/Oncology Pharmacy Association (HOPA) assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CE activities. All relevant conflicts of interest that are identified are thoroughly vetted by HOPA for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. HOPA is committed to providing its learners with high-quality CE activities and related materials that promote improvements of quality in healthcare and not a specific proprietary business interest of a commercial interest.

Reported Areas of Conflict: Planners and Managers Hematology/Oncology Pharmacy Association does not view the existence of relationships as an implication of bias or that the value of the material is decreased. The content of the activity was planned to be balanced, objective, and scientifically rigorous. Occasionally, authors may express opinions that represent their own viewpoint. Conclusions drawn by participants should be derived from objective analysis of scientific data. Unlabeled/unapproved uses of drugs. All faculty have indicated that they have not referenced unlabeled/unapproved uses of drugs and devices.

Individual webinar pricing: $40 (member) / $70 (non-member)

Register Now

This may also be purchased as part of the 2018 BCOP Webinar Bundle.

xs
sm
md
lg